ChartMill is a comprehensive online stock research platform designed to empower traders and investors with advanced tools for technical and fundamental analysis. The company provides a robust stock screener that allows users to filter thousands of stocks across major exchanges like NYSE, NASDAQ, and EURONEXT, using over 180 customizable technical and fundamental parameters to identify trading opportunities.
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest trading volume and driving market activity.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Thursday. Stay informed about the latest market trends.
Full House Resorts (FLL) reported mixed Q3 2025 results, with revenue beating estimates but a wider-than-expected loss. The stock fell despite strong growth from its American Place and Chamonix casinos.
Dentsply Sirona's Q3 earnings missed EPS estimates, causing a sharp stock drop. The company unveiled a new "Return-to-Growth" plan to address performance challenges.
Advantage Solutions (ADV) missed Q3 2025 earnings and revenue estimates, but the stock rose as investors focused on improved net income and a strong cash position.
ScanSource Q1 earnings beat on EPS but missed revenue estimates, causing a stock dip. The company reaffirmed its full-year outlook despite the sales decline.
Invivyd (IVVD) reported mixed Q3 results, with revenue slightly missing estimates but EPS beating forecasts. The stock surged 9% as investors focused on cost control and progress with its new VYD2311 clinical program.
UroGen Q3 2025 results show a revenue miss but a narrower-than-expected loss. The biopharma highlighted strong pipeline progress and the ongoing launch of its new product, ZUSDURI.
Golden Entertainment (GDEN) missed Q3 2025 earnings and revenue estimates, posting a net loss. The stock fell as the company also announced a major strategic transaction.
Dogwood Therapeutics reports a Q3 2025 earnings miss but highlights key progress for its Halneuron® Phase 2b trial, with interim analysis on track for late 2025.
Greystone Housing (GHI) missed Q3 2025 earnings and revenue estimates, causing a stock dip. The company announces a strategic shift back to tax-exempt bonds for stable returns.
Americold's Q3 2025 earnings show a revenue miss but a huge AFFO per share beat. The stock is down pre-market as the company reiterates its full-year outlook.
Backblaze Q3 2025: Earnings beat estimates with strong profit growth, while revenue slightly missed. The company raised its full-year profitability outlook.
NextNav's Q3 2025 earnings show a revenue miss but a narrower-than-expected loss. The company continues strategic progress on its next-gen PNT technology.
Amylyx Pharmaceuticals posts a narrower-than-expected Q3 2025 loss. The company bolsters its cash position, extending its runway into 2028 to fund its clinical pipeline.
Middleby (MIDD) Q3 2025 earnings beat profit forecasts. The company announced a strategic review and a major impairment charge while maintaining strong cash flow.
Marex Group's Q3 2025 results beat EPS and revenue estimates. The financial services firm showed robust growth, with a 23% revenue increase year-to-date and a strong Q4 start.
Discover Uber's affordable growth potential. Strong revenue, soaring earnings, and a reasonable valuation make it a standout for value-focused investors.
GH Research Q3 2025 results show a slight EPS beat. The biotech firm is focused on resolving the FDA clinical hold for its GH001 treatment for depression.
SelectQuote (SLQT) reported mixed Q1 FY2026 results, beating revenue estimates but posting a net loss. The stock fell sharply as investors focused on challenges in its Senior segment.
Madison Square Garden Entertainment (MSGE) beat Q1 earnings estimates despite a slight revenue miss, driven by record concerts and strong event momentum.
Apyx Medical Q3 2025 earnings beat expectations with a 50% EPS surprise and strong revenue. Stock surges on successful AYON Body Contouring System launch.
HanesBrands Q3 2025 results show earnings growth but a revenue miss. The apparel company improved profitability and cut costs, yet sales fell short of analyst expectations.
IBKR stock is a top growth pick, identified by a powerful screen combining Mark Minervini's strong technical Trend Template with fundamental High Growth Momentum filters.
STAGWELL (STGW) Q3 2025 earnings show a slight revenue miss but an EPS beat. The stock surged 60% pre-market on strong growth in digital transformation and a new AI partnership with Palantir.
Harvard Bioscience (HBIO) posted mixed Q3 2025 results, beating on revenue but missing on EPS. Despite the miss, the stock surged as investors focus on strong order growth and a positive restructuring outlook.
Shift4 Payments (FOUR) posts mixed Q3 2025 results, beating EPS estimates but missing revenue forecasts. The stock saw a pre-market gain despite the revenue shortfall.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Under Armour (UAA) beat Q2 FY2026 earnings and revenue estimates, but the stock fell as investor focus shifted to future guidance and outlook concerns.
LSI Industries reported strong Q1 FY26 revenue growth of 14% to $157.3M, beating estimates. However, earnings of $0.23 per share missed expectations, causing a negative market reaction.
